



Investor Presentation

Pareto Securities' Healthcare Conference,
Stockholm September 7, 2022

Klaus Sindahl
Head of Investor Relations

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

Hansa Biopharma today

Successful track record...

Strong momentum...

Promising future...

A validated technology

VALIDATION ACROSS THREE AREAS

- ✓ Approval in kidney transplantations
- ✓ Proof of concept in autoimmune diseases
- ✓ Partnerships to explore gene therapy

Idefirix® is our first approved drug in Europe*

EUROPE KIDNEY TRANSPLANTS

For highly sensitized patients in Europe

Broad pipeline in transplantation and autoimmunity

PROGRAMS IN CLINICAL DEVELOPMENT

US kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

Established a high-performance organization

NEW COMPETENCIES ADDED

145 employees June 2022
(~3x in 3 years)
Highly qualified team with 20 years on average in life science
Purpose driven culture

With current cash position Hansa is financed through 2024

FINANCIALS

SEK 617 in Cash and short term investments (USD ~60m) June 2022
SEK ~1.3bn (USD ~130m) post NovaQuest financing transaction carried out July 2022

Created shareholder value and diversified our ownership base

MARKET CAPITALISATION (USD): ~300m

Listed on Nasdaq Stockholm
18,000 shareholders
Foreign ownership make up ~40% through leading international life science specialist funds




Patient*

This is a break-through for the patients who need but can't access kidney transplantation today

*Idefirix approved in EEA under conditional approval for kidney transplantation

**Actual patient has given consent to provide images

Many milestones achieved during the last 15 months



Imlifidase

A novel approach to eliminate pathogenic IgG


Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection




A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')₂ fragment and one homo-dimeric Fc-fragment




Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



Potential indication universe




*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.

**) In the US a new study has commenced targeting a BLA filing by H1 2024

Our Business model

Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications



Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ← ————— → Higher complexity transplants

~70% of patients^{1,2}

Non or less sensitized
(cPRA < 20%)

15-20% of patients^{1,2}

Moderately sensitized
(20% < cPRA < 80%)

10-15% of patients^{1,2}

Highly sensitized
(cPRA > 80%)

Highly sensitized patients that are likely to be transplanted with a compatible donor

Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients

Potential patients

idefirix®
imlifidase

Actual patient has given consent to provide images



¹ EDQM. (2020). International figures on donation and Transplantation 2019
² SRTR Database and individual assessments of allocation systems

The kidney transplantation landscape in Europe and the U.S.

Up to 15% of patients waiting for a new kidney are highly sensitized

~50,000 transplants done annually in the U.S. and Europe


Breakdown of the kidney transplant waitlist in U.S. and EU



*Reported to be impacted by the COVID-19 pandemic



Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers



Recommendation by NICE is an important step forward for our commercialization efforts and for patients in England, Wales & Northern Ireland

NICE considers Idefirix® to be a clinically- and cost-effective treatment;
Market access has now been secured in 7 European countries and
procedures are ongoing in 11 countries, including Spain and Italy



¹Annual kidney transplantations 2019 (pre-Corona)

^{*}Transplantation data is from Global Observatory on Donation and Transplantation, 2019

^{**}Pricing & reimbursement obtained in France on an early access basis

Broad clinical pipeline in transplantation and auto-immune diseases

Candidate/ Program	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients ^{1,2}							EU: Additional agreements around reimbursement from H2'21
	US: Kidney transplantation in highly sensitized patients ^{1,2}							Completion of enrollment (64 patients) H2'22
	Anti-GBM antibody disease ³							Pivotal Phase 3 study expected to commence in 2022 (50 patients)
	Antibody mediated kidney transplant rejection (AMR)							First data readout H2'22
	Guillain-Barré syndrome (GBS)							Completion of enrollment (30 patients) H2 2022
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)							Preclinical phase
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology							Completion of GLP toxicology studies in 2022
EnzE	Cancer immunotherapy							Research phase

¹ Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)

² Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)

³ Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

Completed

Ongoing

Planned

Post approval study running in parallel with commercial launch

Our unique antibody cleaving enzyme technology may have relevance across a range of indications


Targeting rare IgG mediated diseases

Anti-GBM paves the way for development in other autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

IgG-cleaving enzymes to enable or even potentiate cancer therapy

- Allogeneic stem cell (bone marrow) transplantation (HSCT)
- Enzyme-based antibody Enhancement (EnzE)



Expanding our commercial franchises

- Regulatory approval (conditional)
- Clinical development
- Partnership (preclinical development)
- Preclinical development
- Potential indications (currently not pursued)

Shaping a new standard for desensitization will help enable new indications in transplantations



- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

Exploring opportunities in gene therapy

- Encouraging preclinical data published in Nature
- Validation through collaborations with Sarepta and AskBio
- Wide indication landscape beyond

Hansa Biopharma is financed through 2024


\$70 million non-dilutive financing transaction announced in July 2022 to support the continued development of Hansa's antibody-cleaving enzyme technology platform



*Including SEK ~750m from NovaQuest financing agreement & SEK ~100m upfront payments from Sarepta

Upcoming milestones

Milestones subject to potential COVID-19 impact




Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.



Investor Relations

Visit our web site
www.hansabiopharma.com



Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Calendar and events

Aug 31, 2022

Redeye Late-stage Life Science conference, Stockholm

Sept 7, 2022

Pareto annual Healthcare Conference 2022, Stockholm

Sept 8, 2022

Citi's 17th Annual BioPharma Conference, Boston

Sept 12-13, 2022

H.C. Wainwright Global Investment Conference, New York

Sept 14, 2022

MorganStanley Global Healthcare Conference, New York

Sept 15-16

William Blair US Midwest/West Coast road show

Sept 26, 2022

Aktiespararna Aktiedagen, Lund

Oct 20, 2022

Interim Report for January-September 2022

Oct 20, 2022

Redeye Afterwork presentation, Gothenburg

Oct 21, 2022

Redeye Lunch presentation, Stockholm

Oct 26, 2022

Ökonomisk Ugebrex Life Science Conference, Copenhagen

Nov 23, 2022

SEB Healthcare Seminar 2022, Stockholm

Nov 24, 2022

Redeye Life Science Day, Stockholm

Dec 1, 2022

Erik Penser Banks Temadag - Health Care, Stockholm